Article ; Online: Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.
Travel medicine and infectious disease
2020 Volume 35, Page(s) 101735
Abstract: ... of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients ... risks and strictly rationalise the use of these drugs in COVID-19 patients until further high quality ... In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed ...
| Abstract | The rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), represents an unprecedented serious challenge to the global public health community. The extremely rapid international spread of the disease with significant morbidity and mortality made finding possible therapeutic interventions a global priority. While approved specific antiviral drugs against SARS-CoV-2 are still lacking, a large number of existing drugs are being explored as a possible treatment for COVID-19 infected patients. Recent publications have re-examined the use of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients. In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed the previous studies which used CQ or HCQ as an antiviral treatment. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rationalise the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19. |
|---|---|
| MeSH term(s) | Animals ; Antimalarials/adverse effects ; Antimalarials/blood ; Antimalarials/pharmacokinetics ; Antimalarials/therapeutic use ; Antiviral Agents/blood ; Antiviral Agents/pharmacokinetics ; Antiviral Agents/therapeutic use ; Betacoronavirus/drug effects ; Betacoronavirus/physiology ; Biological Availability ; COVID-19 ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Half-Life ; Humans ; Hydroxychloroquine/adverse effects ; Hydroxychloroquine/blood ; Hydroxychloroquine/pharmacokinetics ; Hydroxychloroquine/therapeutic use ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Treatment Outcome ; Virus Internalization/drug effects ; Virus Replication/drug effects ; COVID-19 Drug Treatment |
| Chemical Substances | Antimalarials ; Antiviral Agents ; Hydroxychloroquine (4QWG6N8QKH) |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-05-06 |
| Publishing country | Netherlands |
| Document type | Journal Article ; Review |
| ZDB-ID | 2170891-5 |
| ISSN | 1873-0442 ; 1477-8939 |
| ISSN (online) | 1873-0442 |
| ISSN | 1477-8939 |
| DOI | 10.1016/j.tmaid.2020.101735 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6236: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.